Clinical Trial Update: EVP-6124 Renal Impairment Study [Phase 1]

View source ↗

Summary

FORUM Pharmaceuticals completed a Phase 1 renal impairment study of EVP-6124 (encenicline) under NCT01984723.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED